#United States #healthcare #San Francisco #Henlius #JPMorgan

Jason Zhu's Keynote at JPM Healthcare Conference 2026

The upcoming J.P. Morgan Healthcare Conference is one of the most anticipated events in the global healthcare investment landscape, and this year it will take place from January 12 to January 15, 2026, in San Francisco, USA. Among the distinguished speakers at this event is Jason Zhu, the CEO of Henlius, who is set to present on January 15.

Recognized for its influence, the J.P. Morgan Healthcare Conference serves as a significant barometer for trends in the pharmaceutical and health sectors. This year, over 8,000 participants are expected to gather, including business leaders, emerging companies, technology innovators, and international investors to explore groundbreaking developments and partnership opportunities.

Henlius' Role in Global Health Innovation

During his address, Dr. Jason Zhu will shed light on the core competencies that Henlius has cultivated throughout its international journey. He will updates on the innovative pipeline and new-generation technology platforms the company has established, including antibody-drug conjugates and multi-specific T-cell activators. This presentation is part of Henlius' broader strategy as it evolves from a startup biotechnology company into a globally recognized biopharmaceutical powerhouse.

Henlius has successfully integrated various aspects of its operations, covering research and development, manufacturing, regulatory affairs, and marketing. The company boasts a robust international presence, with dedicated clinical development and regulatory teams established in key markets such as the United States and Japan. This strategic positioning allows for independent execution of clinical trials and direct engagement with global regulatory authorities, expediting development and market access.

Moreover, Henlius' commercial manufacturing facilities have received Good Manufacturing Practice (GMP) certifications in China, the EU, and the USA, underlining its commitment to quality and safety standards. The company's global supply network now spans across six continents, supporting the coordinated development of differentiated innovation assets and diverse technological platforms.

Looking Ahead: Henlius and Future Challenges

As Henlius continues to strengthen its market presence, it remains dedicated to addressing unmet patient needs worldwide. The company plans to collaborate closely with financial markets and industry partners globally to enhance its innovation and operational capabilities, aiming to provide high-quality and affordable biological medications to patients around the world.

Dr. Zhu's keynote is not only a reflection of Henlius' achievements but also sets the stage for the company’s vision for the future. He will outline strategic perspectives for the next five years, focusing on building a patient-centric biopharmaceutical company that can compete on an international scale while forging long-term strategic partnerships with leading multinational pharmaceutical firms.

About Henlius

Founded in 2010, Henlius (2696.HK) is a global biopharmaceutical company dedicated to the development of high-quality, affordable biological medications, primarily in oncology, autoimmune diseases, and ophthalmic disorders. Their portfolio includes ten approved products in various countries and regions, as well as five market applications currently under review in China and the EU. With its integrated platform that supports every lifecycle stage from R&D to market release, Henlius continues to drive forward its mission of improving global health outcomes.

To learn more about Henlius, visit Henlius Official Website and follow them on LinkedIn.